top of page
Search

Lexaria Bioscience prices $1.6 Million Registered Direct Offering

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery.


Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 1,618,330 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.97. The warrants will become exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $0.97 per share.


The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $1.6 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Maxim Group LLC is acting as the sole placement agent in connection with the offering.


The shares of common stock (or pre-funded warrants in lieu thereof) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333- 262402), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on February 4, 2022. The offering of shares of common stock (or pre-funded warrants in lieu thereof) will be made only by means of a prospectus supplement that forms a part of such registration statement. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws.


This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3500.


About Lexaria Bioscience Corp. Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 36 patents granted and many patents pending worldwide.


For more information, please visit www.lexariabioscience.com.


Source: Lexaria Bioscience Corp.

____________________________________________

Does your company have business or financial objectives?


Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives.


If your company has business or financial objectives check out the strategic advisory services provided by FC Global Strategies

Medical and Pharma Insider is a program of FC Global Strategies.


Click here to schedule a call to discuss your company's business and financial goals.


Contact FC Global Strategies:


Global

Jeffrey Friedland (Based in the US)

+1 646 450 8909

jeffrey@fcglobalstrategies.com


The Middle East, North Africa and Eastern Europe

David Krutonog (Based in Israel

+972 50 974 3429

david@fcglobalstrategies.com


Southeast Asia, Asia-Pacific, Australia, and New Zealand

Ross Swan (Based in Singapore)

+65 9181 9472

ross@fcglobalstrategies.com


Latin America

Claudio Hebling (Based in Brazil)

+55 19 99377 7482

claudio@fcglobalstrategies.com


South Asia

Vincent Paul Joseph (Based in India)

+91 962 620 9090

vincent@fcglobalstrategies.com




bottom of page